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Background/aim: Adrenal incidentalomas have been associated with increased cardiovascular risk and have a prevalence as high as
10%. This study aims to evaluate carotid- intima media thickness (CIMT), left ventricular mass, and epicardial adipose tissue thickness
in nonfunctioning adrenal incidentaloma patients and compare their results with healthy controls.
Materials and methods: Patients who were referred to the endocrinology clinic for adrenal incidentaloma between 2014 and 2019 were
assessed with 1 mg dexamethasone suppression test, 24-h urine metanephrines and normetanephrines, plasma aldosterone to renin
ratio. Age and gender-matched subjects without an adrenal mass formed the control group. Left ventricular mass, epicardial adipose
tissue thickness, and CIMT of both groups were measured.
Results: A total of 41 adrenal incidentaloma patients (21 female, 52.5%) and 40 healthy controls (19 female, 46.3%) were included in
the study. Patients with adrenal incidentalomas had increased CIMT. No differences were observed in left ventricle mass or epicardial
adipose tissue thickness. There was no correlation between CIMT and adenoma size or serum cortisol (p = 0.2 and p = 0.6, respectively).
There was a statistically significant correlation between CIMT and age (p = 0.016, r = 0.295). HBA1c (p = 0.001) and age (p = 0.05) were
independently associated with CIMT in regression analysis.
Conclusion: Adrenal incidentaloma patients need to be monitored for cardiac dysfunction. CIMT may be used to evaluate adrenal
incidentaloma patients for early cardiovascular risk.
Key words: Adrenal incidentaloma, carotid intima-media thickness, epicardial adipose tissue thickness, left ventricular mass

1. Introduction
Adrenal incidentalomas (AI) are defined as adrenal
masses with a diameter >1 cm, discovered on an imaging
test performed for a condition unrelated to adrenal
disease [1]. The incidence of AI has increased over the
years with the widespread use of imaging techniques
for thoracic and abdominal regions [2]. Its prevalence is
1%–8.7% in autopsy series and as high as 10% in older
adults [1].
Adrenal diseases, such as Cushing’s syndrome,
primary aldosteronism, and pheochromocytoma,
pose a risk for cardiovascular disease [3–5]. Moreover,
cardiovascular risk has been reported to increase even
if adrenal incidentalomas are nonfunctioning [6,7].
Metabolically, AI has been associated with type 2 diabetes,
dyslipidaemia, and hypertension [7].

Carotid intima-media thickness (CIMT) and
epicardial adipose tissue thickness (EATT) are considered
to be noninvasive markers of atherosclerosis [8–10]. Left
ventricular mass (LVM) is associated with increased
cardiovascular risk and mortality [11]. Alterations of
these parameters are considered to be predictors of early
cardiovascular disease. In this study, we aimed to evaluate
CIMT, LVM, and EATT in patients with AI and compare
their results with healthy controls.
2. Subjects and methods
2.1. Study population and design
Patients who were referred to the endocrinology clinic
for AI between 2014 and 2019 were evaluated. Adrenal
lesions were discovered by computed tomography (CT)
or magnetic resonance imaging (MRI), which were
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performed for unrelated conditions such as urolithiasis.
The radiologic characteristics of all AI were consistent with
benign cortical adenoma (demarcated lesions less than
4 cm with attenuation values lower than 10 Hounsfield
Units). Patients who were older than 18 years and gave
written consent were included in the study. Laboratory
tests including 1 mg dexamethasone suppression test, 24-h
urine metanephrines, and normetanephrines, plasma
aldosterone to renin ratio were performed to detect any
functional adrenal masses. If serum cortisol after 1 mg
overnight dexamethasone suppression test was above
1.8 mcg/dL, a two-day (2 mg) dexamethasone test was
administered. Patients with functioning adenomas were
excluded.
Patients diagnosed with diabetes according to the
criteria of the American Diabetes Association were
excluded (diabetes mellitus was defined as fasting plasma
glucose >126 mg/dL (7 mmol/L), oral glucose tolerance
test 2h plasma glucose >200 mg/dL (11.1 mmol/L) and
HbA1c ≥6.5%). Patients on antihypertensive treatment
or with systolic blood pressure higher than 140 mmHg
and/or diastolic blood pressure higher than 90 mmHg
were also excluded. Patients with a body mass index
(BMI) above 35 were excluded. Patients with documented
cardiovascular or cerebrovascular disease or malignancy
were also excluded.
Control subjects were recruited from the cardiology
clinic among individuals who presented with nonspecific
complaints including dyspepsia and noncardiac chest
pain with incidental abdominal imaging available in the
electronic medical records of the hospital. Subjects without
cardiovascular disease, hypertension, diabetes mellitus,
dyslipidaemia, obesity, and medication use were included
as control subjects. Echocardiographic examination of
both groups was performed by the same cardiologist.
Ethics approval of the study was obtained from the
university ethics committee. Helsinki Declarations were
followed and written informed consent was obtained from
all participants.
2.2. Cardiac assessment
Participants were assessed with Philips EPIQ 7
ultrasonography system and an S5-1 probe. Transthoracic
M-mode, two-dimensional, and subsequent standard and
pulsed tissue Doppler echocardiographic examinations
were done at the lateral decubitus position. Images were
reviewed by the same cardiologist blinded to the patients’
information. Left ventricular (LV) ejection fraction
and the LV and left atrial diameters were measured on
M-mode traces recorded in the parasternal long-axis view
compatible with standards. LVM was calculated with Penn
equation [12].
EATT was defined as the relatively echo-free space
between the outer wall of the myocardium and the visceral
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layer of the pericardium. It was measured perpendicularly
on the free wall of the right ventricle at end-systole in 3
cardiac cycles and measured perpendicularly from the free
wall of the right ventricle at end-diastole. The maximum
EATT was measured from the point on the free wall of the
right ventricle along the mid-line of the ultrasound beam
perpendicular to the aortic annulus as a landmark [13].
CIMT was measured with T8, a general electric
ultrasonography system, and a 6-13 MHz GE L6-12-RS
linear array transducer. It was defined as the distance
between lumen-intima and the media-adventitia of the
carotid arterial wall on the ultrasound. Carotid artery
measurements were obtained in the supine position. The
right and left common carotid artery proximal to the
carotid bulb was imaged in multiple longitudinal planes for
the best resolution of the intima media thickness of the far
wall. CIMT was measured by manually tracing the intimamedia wall of the artery. Three points were measured on
one scan and were synchronized with R-wave peaks on the
electrocardiography to avoid errors resulting from variable
arterial compliance. The mean CIMT was calculated from
six measurements taken from two scans [14].
2.3. Statistical analysis
Statistical analysis was performed using the SPSS software
version 16. Normality of the variables was tested using
visual (histogram) and analytic methods (Kolmogorov–
Smirnov/Shapiro–Wilk’s test) to determine whether
they are normally distributed. Mann–Whitney U test
was conducted to compare parameters among groups.
Pearson’s and Spearman’s tests were used to measure
correlations between variables. Multiple linear regression
analyses using the stepwise method were performed to
assess the independent variables affecting the dependent
variable CIMT. All independent variables in the multiple
linear regression were checked for multicollinearity. If the
variance inflation factor (VIF) exceeded 3.0, the variable
was considered to be collinear. All reported confidence
interval (CI) values were calculated at the 95% level. An
overall 5% type-I error level was used to infer statistical
significance.
3. Results
One hundred and twenty patients diagnosed with AI were
evaluated. A total of 81 participants (40 female, 49.4%)
who met the inclusion criteria were included in the study.
There were 41 patients (21 female, 52.5%) in the AI group
and 40 patients in the control group (19 female, 46.3%).
The demographic characteristics of the participants are
shown in Table 1. There were no significant differences
with respect to age, gender, BMI, or smoking habits
(pack-years) between the two groups. The majority of the
adenomas were on the left side (26; 59%). Two patients had
bilateral adenomas.
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Table 1: Demographic, laboratory, and clinical characteristics.
Incidentaloma group
(n = 41)

Control group
(n = 40)

p value

Age (years)

52.9 ± 11.5

48.5 ± 10.9

0.08

Male/female (n/n)

19/22

21/19

0.65

Body-mass index (kg/m2)

25.5 ± 2.0

22.5 ± 2.1

0.23

Systolic BP (mmHg)

117.2 ± 8.9

117.5 ± 8.1

0.87

Diastolic BP (mmHg) median (IQR)*

70 (70–70)

80 (70–80)

<0.001**

Heart rate (beat/min) median (IQR)*

70 (64–76)

75 (69,5–78)

0.057

Triglyceride (mg/dL)

132.3 ± 70.7

176.1 ± 78.0

0.02**

HDL cholesterol (mg/dL)

57.2 ± 16.7

45.4 ± 18.0

0.03**

LDL cholesterol (mg/dL)

143.2 ± 44.7

136.0 ± 36.7

0.49

* Mann–Whitney U test.
** Statistically significant.
BP: Blood pressure; HDL: High-density lipoprotein; IQR: Interquartile range; LDL: Low-density lipoprotein.
If not otherwise stated, all data are presented as mean ± standard deviation.

Patients with AI had significantly higher high-density
lipoprotein (HDL) cholesterol levels than controls
(57.2±16.7 vs. 45.4±18.0, p = 0.03). Control subjects
had higher triglyceride levels than patients (132.3±70.7
vs.176.1±78.0, p = 0.02). Diastolic blood pressure of the
control group was higher than the AI group (p < 0.001).
Patients with AI had statistically greater CIMT values
(0.57±0.15 vs. 0.49± 0.13, p = 0.038). No differences were
observed between the two groups regarding LVM or EATT
(Table 2). While the LV ejection fraction was within the
normal range in both groups, it was lower in AI patients
than in controls (64.0±7.5 vs. 68.5±5.2, p = 0.008). Mitral
E was lower and mitral E deceleration time was longer in
AI patients than in controls (69.5±17.3 vs. 79.9±20.2, p =
0.02; 178.0±47.5 vs. 127.1±33.6, p < 0.001; respectively).
There was no correlation between CIMT, adenoma size
and serum cortisol (p = 0.2 and p = 0.6, respectively).
There was a statistically significant correlation between age
and CIMT (p = 0.016, r = 0.295).
Parameters affecting CIMT were then evaluated by
multivariate analysis. Statistically significant parameters
and parameters likely to affect the CIMT were included in
the model. In this context, the relationship between CIMT
and age, gender, BMI, HbA1c, adenoma size, creatinine,
LDL-C, HDL-C, systolic blood pressure (SBP), diastolic
blood pressure (DBP), cortisol level, and smoking were
evaluated. HBA1c (p = 0.001) and age (p = 0.05) were
independently associated with CIMT in regression
analysis (Table 3).
4. Discussion
In this study, we found that CIMT was increased in
patients with AI compared to healthy controls. However,

no significant difference was observed between the two
groups with respect to LVM or EATT.
It is plausible that cardiovascular risk is increased
in patients with an adrenal adenoma and subclinical
Cushing’s syndrome. Subtle production of cortisol
hormone can lead to metabolic abnormalities even in the
absence of clinically apparent diabetes or hypertension
[15]. Metabolic disturbances may lead to cardiac changes
such as increased LVM and EATT, which is the visceral fat
tissue of the heart. It has been suggested that excess EATT
may contribute to increased LVM as an end-organ damage
[16]. Still, the causes of these cardiac complications are not
clearly understood.
Interestingly, even nonfunctioning adenomas have
been shown to cause metabolic disturbances such as
insulin resistance. Increased levels of proinflammatory
cytokines have been proposed as a possible explanation
for the metabolic dysfunction in nonfunctioning adrenal
adenomas [17,18].
We found CIMT to be significantly increased in
patients with AI. Our finding is in line with Imga et al.’s
study assessing cardiovascular indices in patients with
AI [19]. It is a relatively easy and noninvasive method for
showing early signs of atherosclerosis and is considered
reliable in this population. Evran et al. have proposed that
CIMT be used as a risk indicator for metabolic syndrome
screening in AI patients [20].
Iacobellis et al. [16] have shown that EATT and
LVM are greater in patients with AI. However, the study
participants were relatively older compared to our cohort.
An older age group could have been presented with fullblown cardiac manifestations of AI, including increased
EATT and LVM.
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Table 2: Comparison of echocardiographic measurements.
Incidentaloma group
(n = 41)

Control group
(n = 40)

p value

IVS (cm), median (IQR)*

0.9 (0.9–1,0)

1.0 (0.9–1.0)

0.43

PW (cm), median (IQR)*

0.9 (0.8–0.9)

0.9 (0.8–0.9)

0.62

LVDD (cm)

4.5 ± 0.3

4.6 ± 0.4

0.24

LVSD (cm)

2.6 ± 0.3

2.8 ± 0.3

0.02**

EF (%)

64.0 ± 7.5

68.5 ± 5.2

0.008**

LVM (cm)

158.3 ± 38.0

159.7 ± 39.3

0.86

Mitral E max (cm/s)

69.5 ± 17.3

79.9 ± 20.2

0.02**

Mitral A max (cm/s)

69.0 ± 15.5

65.5 ± 16.5

0.37

Mitral E deceleration time (ms)

178.0 ± 47.5

127.1 ± 33.6

<0.001**

E’ (septal E)

7.8 ± 2.3

9.0 ± 2.4

0.4

A’ (septal A)

8.5 ± 1.8

6.7 ± 2.1

<0.001**

EATT (mm)

4.8 ± 1.4

4.7 ± 0.9

0.82

CIMT (mm)

0.57 ± 0.15

0.49 ± 0.13

0.038**

* Mann–Whitney U test.
** Statistically significant.
IVS: Interventricular septum; PW: Posterior wall; LVDD: Left ventricular diastolic diameter; LVSD: Left
ventricular systolic diameter; EF: Ejection fraction; LVM: Left ventricular mass; IQR: Interquartile range;
EATT: Epicardial adipose tissue thickness; CIMT: Carotid intima-media thickness.
If not otherwise stated, all data is presented as mean ± standard deviation.

High-density lipoprotein (HDL) cholesterol levels of
AI patients were higher, and triglyceride levels lower than
controls. Hence, patients with AI had a better lipid profile,
which might have neutralized the negative effect of AI on
cardiac adipocytes. In addition, the control group had
a higher diastolic blood pressure. The atherogenic lipid
profile, together with higher diastolic blood pressure, might
explain why we failed to show a significant difference in
EATT and LVM between the two groups. Iacobellis et
al. also reported higher HDL levels [16] and Imga et al.
reported lower triglyceride levels in AI patients [19]. These
incompatible results raise the question of whether there is a
different mechanism responsible for the cardiac changes in
AI. Ermetici et al. have investigated the effect of adipokines
on AI and found higher levels of plasma interleukin-6 (IL6), adiponectin, resistin, tumour necrosis factor alpha, and
monocyte chemoattractant protein -1 in patients with AI
compared to controls [17]. AI patients had significantly
elevated IL-6, secreted from the adrenal gland, irrespective
of plasma cortisol levels. Ermetici et al. have associated
elevated adipokine levels with atherosclerosis and left
ventricular remodelling regardless of the presence of obesity
or insulin resistance [17]. In the present study, BMI values of
AI patients were numerically greater than controls, although
not statistically significant. It is possible that blood adipokine
levels (rather than visceral fat, dyslipidaemia or insulin
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resistance) determine the extent of the cardiac damage in AI
patients, which might explain why some patients undergo
LVM and EATT changes and some do not. Our study would
have been more conclusive if we had measured adipokine
levels and correlated them with cardiac parameters.
While the LV ejection fraction was within the normal
range in both groups, it was lower in AI patients than in
controls. A subclinical impairment in LV systolic function
may account for this finding. Subclinical impairment in LV
systolic function might have been confirmed by reduced
longitudinal strain in speckle tracking echocardiography
in the AI group.

Mitral E max values were lower, and
deceleration time was longer in AI patients compared to
healthy controls, indicating a diastolic dysfunction. Imga
et al. has found no difference between patients and controls
regarding EF [19]. De et al. have similarly reported reduced
EF and E/A ratio (the ratio between E-wave and A-wave)
in AI patients [21]. Even if the LV ejection fraction is
preserved, it may be reasonable to monitor AI patients for
both systolic and diastolic cardiac dysfunction.
HbA1c and age were the only parameters independently
associated with CIMT in regression analysis. It is not
unexpected that unregulated blood glucose and older age
increase CIMT. However, a larger sample size might reveal
further associations between CIMT and other metabolic
parameters.
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Table 3. Factors relaed to CIMT in stepwise multiple linear regression analysis.
Coefficientsa
Unstandardized
Coefficients

Standardized
Coefficients p value

B

Std. Error

Beta

(Constant)

–1.252

0.116

HbA1c

0.332

0.024

1.113

0.001

Age

–0.004

0.001

–0.258

0.050

Collinearity
Statistics

p value

Model

0.002

a.
Dependent variable: CIMT
Excluded Variablesa

B

Partial
Correlation

Male

–0.082

–0.665

0.885

0.335

BMI

–0.106

–0.425

0.218

0.575

Adenoma size

–0.106

–0.577

0.405

0.423

Creatinine

–0.080

–0.510

0.551

0.490

LDL cholesterol

–0.009

0.096

–0.039

0.241

HDL cholesterol

0.067

0.412

0.511

0.588

Systolic BP

0.132

0.594

0.276

0.406

Diastolic BP

0.094

0.601

0.558

0.399

Cortisol

–0.077

–0.513

0.606

0.487

Smoking

–0.130

–0.406

0.133

0.594

Model

Tolerance

a. Dependent variable: CIMT.
b. Correlates in the model: (Constant), HbA1c, age.
BMI: Body mass index; BP: Blood pressure; CIMT: Carotid intima-media thickness;
HbA1c: Glycated hemoglobin; HDL: High-density lipoprotein; LDL: Low-density
lipoprotein.

Our study has some limitations. First, our sample size
was relatively small. Second, we were not able to relate the
increased CIMT to increased cardiovascular events in AI
patients; the clinical relevance of our findings remains
to be elucidated. The fact that our study has different
results compared to previous studies on AI patients
indicate heterogeneity among AI patients. Further studies
with larger sample sizes are warranted to explain the
contradictory results in the literature.
Our study also has several strengths. Previous research
has shown an increased occurrence of cardiovascular
events related to the subclinical secretion of cortisol in
AI patients [22]. However, research on the cardiovascular
effects of nonfunctioning adrenal adenomas is still scarce.
In addition, reports of AI generally have a higher ratio of
female patients, whereas our study had a gender ratio of
one.

In conclusion, we found that patients with AI had
increased CIMT compared to controls. However,
this difference was not observed for EATT or LVM.
Cardiovascular risk is increased even in nonfunctioning
adrenal incidentalomas; hence, patients need to be
monitored for cardiac dysfunction. In light of our findings,
CIMT may be used to assess early cardiovascular risk in
relatively young AI patients. With the increased utilization
of thoracic imaging due to the COVID-19 pandemic,
clinicians will most likely see a surge in AI cases.
Prospective studies with larger sample sizes should be
designed to investigate the changes in CIMT, EATT, and
LVM in AI patients and their relation to cardiovascular
morbidity and mortality.
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